| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05261399 | Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants… | Carcinoma | Active, Not Recruiting |
| NCT03091192 | Savolitinib vs. Sunitinib in MET-driven PRCC. | Carcinoma | Active, Not Recruiting |
| NCT05043090 | Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven… | Papillary Renal Cell Carcinoma | Active, Not Recruiting |
| NCT05009836 | Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced… | Non-small Cell Lung Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT05620628 | Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified… | Stomach Cancer, Adenocarcinoma | Recruiting |
| NCT06563999 | Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare… | Lung Cancer Stage III | Recruiting |
| NCT03778229 | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | Carcinoma | Active, Not Recruiting |
| NCT05374603 | Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC | Lung Cancer | Active, Not Recruiting |